also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Express Scripts Holding


Express Scripts Holding


In 2017, pharmacy benefits giant Express Scripts saw its net income skyrocket by 33% year-over-year to $4.51 billion. But a healthy chunk of that income — $1.38 billion — was attributable to the tax law signed by President Donald Trump late last year. While Scripts touted investments in its workforce as a result of the corporate tax cut, it also repurchased 45.9 million of its shares in a stock buyback of nearly $2.95 billion. In 2018, the company will be sure to keep an eye on potential pushback on benefits managers at large, which some critics say contribute to high drug prices because of the industry’s convoluted drug rebate structure. Express Scripts is also in the midst of a proposed $54 billion megadeal to be purchased by insurer Cigna.

Looking for leads, investment insights, or competitive intelligence?


Timothy C. Wentworth

CEO Title

President, Chief Executive Officer & Director


Health Care


Health Care: Pharmacy and Other Services

HQ Location

St. Louis

Years on Fortune 500 List




Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$100,065-0.2%
Profits ($M)$4,517.432.7%
Assets ($M)$54,256
Total Stockholder Equity ($M)$18,120
Market Value — as of March 29, 2018 ($M)$38,791
Profit Ratios
Profit as % of Revenues4.5%
Profits as % of Assets8.3%
Profits as % of Stockholder Equity24.9%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)7.74
EPS % Change (from 2016)43.6%
EPS % Change (5 year annual rate)34.5%
EPS % Change (10 year annual rate)21.8%
Total Return
Total Return to Investors (2017)8.5%
Total Return to Investors (5 year, annualized)6.7%
Total Return to Investors (10 year, annualized)7.4%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Express Scripts Holding

PBMs Are Hogging Our Drug Discounts

Kudos to Trump for taking them on.

Read More →
What Carl Icahn Said In His Brutal Letter Slamming the Cigna-Express Scripts Deal

Icahn isn't mincing words, urging Cigna shareholders to reject the $60 billion proposed deal.

Read More →
Why Trump's Big Drug Price Speech Sent Health Care Stocks Soaring

The president's drug price proposals didn't shake big pharma and other health care companies.

Read More →